Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of DWP16001 in subjects with hepatic impairment compared with subjects with normal hepatic function.
Official title: An Open-label, Multi-center, Parallel, Single Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of DWP16001 in Subjects With Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Key Details
Gender
All
Age Range
19 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2023-04-13
Completion Date
2024-04-30
Last Updated
2024-04-08
Healthy Volunteers
Yes
Conditions
Interventions
DWP16001
0.3mg
Locations (1)
Seoul National University Hospital
Seoul, South Korea